Argus analyst Kevin Heal started Ameriprise Financial with a Buy rating and a price target of $177, saying the company generated "steady" revenues over the recent quarters thanks to the "strong wrap flows" and rising short-term interest rates. While the flattening yield curve and a shift in the Fed interest rate policy pose more recent challenges, the analyst contends that Ameriprise Financial will be able to derive growth from equity market volatility, an increase in fee-based accounts, and future revenues from Ameriprise Bank. Heal adds that the valuation on Ameriprise Financial shares is attractive at 9-times his expected FY19 earnings multiple, which is below the company's historical average of 11-times and the peer average of 13-times.

RBC Capital raised the firm's price target on Ameriprise to $480 from $470 and keeps an Outperform rating on the shares after its Q1 earnings beat. The firm continue to sees potential benefit for Ameriprise if clients start to re-allocate cash to wrap accounts or other risk assets, also noting that it is favoring the strong fundamentals in the Advice & Wealth Management Segment business and the stock's capital-return story, the analyst tells investors in a research note.